Clinic
ST. Mary's Community Hospital
ST. Mary's Community Hospital was paid $2.56M by Medicaid between Jan 2018 and Nov 2024, across 66 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoST. MARY'S COMMUNITY HOSPITAL
NEBRASKA CITY, NE 68410
NEBRASKA CITY, NE 68410
33aNPI1528016995assigned 05/05/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$2.56M
24GClaims45,946
24DCodes billed66
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Nebraska
Rank by total paid#8 of 35
Median peer was paid$190K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,255 | $331K | |
| 2019 | 5,009 | $338K | |
| 2020 | 5,592 | $303K | |
| 2021 | 13,026 | $652K | |
| 2022 | 12,317 | $591K | |
| 2023 | 3,454 | $227K | |
| 2024incomplete | 1,293 | $115K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 3,445 | 3,152 | $772K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 1,657 | 1,466 | $517K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.0% | 340 | 279 | $127K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.7% | 6,215 | 5,372 | $120K |
| 80053 | Comprehensive metabolic panel | 4.0% | 4,115 | 3,612 | $103K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 1,014 | 976 | $69K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.6% | 504 | 472 | $67K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 643 | 554 | $64K |
| 80050 | General health panel | 2.0% | 882 | 791 | $52K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 313 | 280 | $40K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 224 | 214 | $35K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 698 | 526 | $35K |
54 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 844 | $30K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 333 | $28K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 2,541 | $27K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.0% | 209 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,215 | $24K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 759 | $23K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 425 | $22K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 549 | $22K |
| 80061 | Lipid panel | <1% | 1,432 | $21K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,059 | $19K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 213 | $19K |
| 71045 | Radiologic examination, chest; single view | <1% | 285 | $18K |
| 87660 | <1% | 459 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 643 | $16K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 694 | $16K |
| 81001 | <1% | 1,965 | $15K | |
| 87480 | <1% | 453 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 835 | $14K |
| 87510 | <1% | 439 | $14K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 313 | $13K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 354 | $13K |
| J3490 | Unclassified drugs | <1% | 2,560 | $12K |
| 87420 | <1% | 29 | $12K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 810 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,178 | $12K |
| 87081 | <1% | 709 | $11K | |
| 86710 | <1% | 172 | $10K | |
| 84484 | <1% | 170 | $9K | |
| 81025 | <1% | 620 | $9K | |
| 83880 | <1% | 108 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 641 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 65 | $5K |
| 87631 | <1% | 32 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 58 | $4K |
| 81003 | <1% | 535 | $4K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 46 | $4K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 50 | $3K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 254 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 68 | $3K |
| 83690 | <1% | 83 | $2K | |
| 83605 | <1% | 116 | $2K | |
| 85018 | <1% | 265 | $1K | |
| 87807 | <1% | 19 | $1K | |
| 83655 | <1% | 47 | $1K | |
| 84439 | <1% | 93 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 42 | $1K |
| 87077 | <1% | 25 | $741.12 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $375.78 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 32 | $366.44 |
| 86803 | <1% | 16 | $354.60 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 970 | $245.90 |
| J2704 | Injection, propofol, 10 mg | <1% | 23 | $107.22 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15 | $84.02 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKUIPER, EVERT (CEO - CHI HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.